An exploratory subgroup analysis of the IMpower150 phase III randomized trial had shown an overall survival benefit in favor of carboplatin plus paclitaxel plus bevacizumab plus atezolizumab versus carboplatin plus paclitaxel plus bevacizumab in the subgroup of patients enrolled in the trial with EGFR mutant advanced NSCLC pretreated or not with EGFR TKIs [61]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.